Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Nat Cancer. 2024 Jan;5(1):114-130. doi: 10.1038/s43018-023-00692-y. Epub 2024 Jan 4.

Abstract

De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical intervention in 43 de novo metastatic prostate cancers to assess somatic genotypes across 607 synchronous primary and metastatic tissue regions plus circulating tumor DNA. Intra-prostate heterogeneity was pervasive and impacted clinically relevant genes, resulting in discordant genotypes between select primary restricted regions and synchronous metastases. Additional complexity was driven by polyclonal metastatic seeding from phylogenetically related primary populations. When simulating clinical practice relying on a single tissue region, genomic heterogeneity plus variable tumor fraction across samples caused inaccurate genotyping of dominant disease; however, pooling extracted DNA from multiple biopsy cores before sequencing can rescue misassigned somatic genotypes. Our results define the relationship between synchronous treatment-sensitive primary and metastatic lesions in men with de novo metastatic prostate cancer and provide a framework for implementing genomics-guided patient management.

MeSH terms

  • Biopsy
  • Genotype
  • Humans
  • Male
  • Precision Medicine*
  • Prostate / pathology
  • Prostatic Neoplasms* / genetics